Medicare GLP-1 Coverage for Weight Loss Starts July 2026: What You Need to Know

For years, the hardest conversation I have had in the clinic wasn’t about the science of obesity—it was about Medicare coverage. Medicare Part D has always had a carve-out for anti-obesity medications as a class. But there was a significant exception: if you had an FDA-approved secondary indication, you may already qualify for coverage. Wegovy (semaglutide) is covered for cardiovascular risk reduction in people with established cardiovascular disease. Zepbound (tirzepatide) is covered for obstructive sleep apnea. Unless you had one of those specific diagnoses, the default was a flat denial. That changes on July 1, 2026. The Centers for Medicare & Medicaid Services (CMS) has officially finalized the Medicare GLP-1 Bridge. This is a locked-in, automatic coverage pathway that will expand access to these medications for the weight loss indication alone—without requiring a separate qualifying diagnosis.

The $50 Monthly Copay

Starting July 1, 2026, eligible Medicare Part D beneficiaries will pay a flat $50 monthly copay for covered anti-obesity medications. This program runs through December 31, 2027. It includes the major medications currently approved for weight loss:

• Wegovy (semaglutide)
• Zepbound (tirzepatide)
• Foundayo (orforglipron)

You do not need to call your insurance agent. You do not need to opt-in or switch your Part D plan. The coverage is automatic for eligible beneficiaries. Under the Bridge, Part D plan sponsors carry zero financial risk—CMS is funding this directly.

Who Qualifies?

For you to qualify for the Medicare GLP-1 Bridge, a provider must submit a prior authorization request that attests the beneficiary meets the following criteria:

• • The beneficiary is prescribed the requested drug to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the applicable FDA approved label, AND
    • The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (≥35) at the time of initiation of GLP-1 therapy, or
    • The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (≥30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: (A) heart failure with preserved ejection fraction, (B) uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications), or (C) chronic kidney disease stage 3a or above, or
    • The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (≥27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: (A) pre-diabetes (as defined by American Diabetes Association guidelines), (B) previous myocardial infarction, (C) previous stroke, or (D) symptomatic peripheral artery disease.

Coverage operates outside the standard Medicare Part D benefit for the duration of the demonstration (July 1, 2026 – December 31, 2027). Prior authorization is required, and your prescribing provider will need to attest that you met the BMI criterion at the time therapy was initiated. For full details, visit the official CMS page: Medicare GLP-1 Bridge | CMS

A Word on Cost

The $50 monthly copay is real progress. But it is worth being direct: depending on your medication and your pharmacy, the list price can still be significant even after the bridge discount. Some patients on higher doses may face additional cost variability. If affordability is a concern, talk to your doctor about whether a lower-cost option or patient assistance program makes sense for your situation.

Why the Shift? The End of the BALANCE Model

If you have been following the news, you might remember the “BALANCE Model.” This was originally supposed to be the way Medicare covered these drugs in 2027, pairing medication access with mandatory lifestyle support programs. On April 21, 2026, CMS abruptly cancelled the BALANCE Model for Medicare Part D. Tying medication access to mandatory lifestyle hoops simply creates another barrier to care. Instead, they extended the GLP-1 Bridge through the end of 2027 to ensure immediate, uninterrupted access to these medications. Note: The Medicaid version of the BALANCE Model is still launching in May 2026, but that is entirely separate from Medicare Part D.

What This Means for You

If you are on Medicare Part D and have been struggling with your weight, the Bridge opens the door for coverage you may not have had before—even if you already use one of these medications for a different indication. The key is talking to your doctor now about where you stand and getting your care plan in place before July 1. We finally have a system that recognizes obesity as a treatable disease for our Medicare patients. It is about time. Ethan Lazarus, MD, MFOMA Clinical Nutrition Center Greenwood Village, CO (303) 750-9454